Literature DB >> 9443942

Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.

C Marbeuf-Gueye1, H J Broxterman, F Dubru, W Priebe, A Garnier-Suillerot.   

Abstract

The multidrug resistance protein (MRP) has been shown to mediate ATP-dependent efflux of anticancer agents of diverse structure, such as daunorubicin (DNR), vincristine and etoposide. Thus, this protein does confer a multidrug resistant phenotype to cancer cells, similar to P-glycoprotein (Pgp). The substrate specificity of both transporter proteins is partly overlapping but is otherwise very distinct; because MRP is a multiple organic anion transporter, it transports certain glutathione conjugates and may be partly dependent on intracellular glutathione levels for the transport of anthracyclines. We have studied the transport kinetics of a series of anthracyclines in MRP and Pgp that overexpress tumor cell lines to obtain information on the substrate specificity of these proteins. The anthracyclines have modifications in the sugar moiety. The mean active efflux coefficient Ka, used to characterize the efficiency of the active efflux, was very similar for DNR and one of its 4'-deoxy-derivatives (eso-DNR) for MRP and Pgp [10-20 x 10(-10)/sec/(cells/ml)]. The permanently neutral derivatives 3'-deamino-3'-hydroxy-doxorubicin (OH-DOX) and 3'-deamino-3'-hydroxy-daunorubicin (OH-DNR) were effluxed by both proteins but had a lower Ka [2 x 10(-10) and 6 x 10(-10)/sec/(cells/ml) (OH-DOX)] and 2 x 10(-10) and 5 x 10(-10)/sec/(cells/ml) (OH-DNR)] for MRP and Pgp. Two anthracyclines, the doxorubicin derivative pirarubicin and 2'-bromo-4'-epi-DNR seemed to have a slightly higher Ka value for Pgp than for MRP. The apparent Michaelis-Menten constants (K(m)) and maximal efflux rates (VM) for the active transport were within a narrow range for both transporters, except for OH-DOX and OH-DNR, which had a lower VM in the case of MRP-mediated transport, suggesting a role of the amino group in the interaction with glutathione. Determination of the Hill coefficient (nH) of the MRP-mediated efflux gave most values close to 2, which suggests cooperativity of the transport of anthracyclines as reported before for Pgp. In conclusion, the transport kinetics of anthracyclines by MRP and Pgp are very similar.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443942     DOI: 10.1124/mol.53.1.141

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  Decrease of P-glycoprotein activity in K562/ADR cells by MbetaCD and filipin and lack of effect induced by cholesterol oxidase indicate that this transporter is not located in rafts.

Authors:  Paiboon Reungpatthanaphong; Carole Marbeuf-Gueye; Laurence Le Moyec; Milena Salerno; Arlette Garnier-Suillerot
Journal:  J Bioenerg Biomembr       Date:  2004-12       Impact factor: 2.945

2.  Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.

Authors:  J Tarasiuk; B Stefańska; I Plodzich; K Tkaczyk-Gobis; O Seksek; S Martelli; A Garnier-Suillerot; E Borowski
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.

Authors:  Milena Salerno; Maria Petroutsa; Arlette Garnier-Suillerot
Journal:  J Bioenerg Biomembr       Date:  2002-04       Impact factor: 2.945

4.  The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children's Oncology Group and NRG Oncology study ARST1321.

Authors:  J Gartrell; J C Panetta; S D Baker; Y L Chen; D S Hawkins; A Ostrenga; T J Scharschmidt; S L Spunt; D Wang; A R Weiss
Journal:  Cancer Chemother Pharmacol       Date:  2022-01-27       Impact factor: 3.333

5.  Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.

Authors:  Ping Ma; Xiaowei Dong; Courtney L Swadley; Anshul Gupte; Markos Leggas; Harry C Ledebur; Russell J Mumper
Journal:  J Biomed Nanotechnol       Date:  2009-04       Impact factor: 4.099

6.  Kinetic analysis of rhodamines efflux mediated by the multidrug resistance protein (MRP1).

Authors:  Chantarawan Saengkhae; Chatchanok Loetchutinat; Arlette Garnier-Suillerot
Journal:  Biophys J       Date:  2003-09       Impact factor: 4.033

7.  Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin.

Authors:  Elene Pereira-Maia; Arlette Garnier-Suillerot
Journal:  J Biol Inorg Chem       Date:  2003-05-17       Impact factor: 3.358

Review 8.  Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators.

Authors:  Ahmad R Safa
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-01

9.  Bis(thiosemicarbazone) copper complexes: mechanism of intracellular accumulation.

Authors:  Catherine Lambert; Heloisa Beraldo; Nicole Lievre; Arlette Garnier-Suillerot; Pierre Dorlet; Milena Salerno
Journal:  J Biol Inorg Chem       Date:  2012-10-27       Impact factor: 3.358

10.  Correlation between multi-drug resistance-associated membrane transport in clonal cancer cells and the cell cycle phase.

Authors:  Vasilij Koshkin; Sergey N Krylov
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.